A cost comparison method is used by NICE if a health technology is likely to provide similar health benefits at a similar cost than medicines recommended in a published NICE technology appraisal guidance for the same indication.⁴

To read more about the NICE recommendation for NGENLA, click here.

The NHS list price of NGENLA is £6.92/mg equivalent to an estimated annual cost of £7,125 for a 30kg patient.

Yearly cost of treatment for a 30kg pGHD patient using NHS list prices^5†

† Please note, this graph does not compare the clinical efficacy of the products mentioned. All costs calculated assume that patients will take their medicine as prescribed- every day for 365 days a year for daily growth hormone and every week for 52 weeks for NGENLA.
The cost/mg values that have been used for each brand are⁵: Saizen: £23.18, Norditropin: £22.22^‡, Nutropin AQ: £20.30, Humatrope: £18.00, Genotropin: £17.39, Zomacton: £17.07, and Biosimilar Omnitrope: £14.75
‡ Please note as Norditropin has a price range of £21.27-£23.18, an average price of £22.22 has been used. 

NGENLA delivered a favoured treatment experience for patients and caregivers in a phase 3 crossover study versus daily Genotropin (somatropin) in pGHD, demonstrating a lower treatment burden and higher intention to comply.^6,7

For safety & efficacy data click here.

Study Design  
Patients and caregivers (N=87) reported improved (lower) Life Interference total score after 12 weeks of once-weekly NGENLA treatment compared to once-daily GH.^6,7 Phase 3, randomised, open-label, 2-period, crossover, multicentre study assessing patient perception of treatment burden with the use of NGENLA once weekly versus Genotropin once daily in children 3 to <18 years of age with GH deficiency.^6,7

Data are based on patient/caregiver recall following each 12-week treatment period and at the end of the study. Caregivers completed the assessment for children under 8 years of age.^6,7
† Based on Patient Global Impression Severity-Impact on Daily Activities.⁷